CSNpharm
Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.
More Information
Supplier Page
CSNpharm
Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.
More Information
Supplier Page
CSNpharm
MK-5172 inhibits Hepatitis C virus NS3/4a protease with Ki of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.
More Information
Supplier Page
CSNpharm
MK-5172 inhibits Hepatitis C virus NS3/4a protease with Ki of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.
More Information
Supplier Page
CSNpharm
Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
More Information
Supplier Page
CSNpharm
Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
More Information
Supplier Page
CSNpharm
Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
More Information
Supplier Page
CSNpharm
Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
More Information
Supplier Page
CSNpharm
Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
More Information
Supplier Page
CSNpharm
Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
More Information
Supplier Page